Suppressed by Design: The Power
Dynamics Behind Peptide Restrictions

In September 2023, the FDA quietly moved 19 peptides into a regulatory category that made them effectively illegal to compound and prescribe through licensed pharmacies across the United States. No major press conference. No broad public debate. Just a bureaucratic designation — Category 2 of the 503A bulks list — that overnight stripped millions of Americans of access to therapies their doctors were prescribing.

The official explanation was safety: concerns over immunogenicity, manufacturing impurities, and insufficient large-scale clinical trials. But when you trace the downstream effects of that decision — who lost, who gained, and what the data actually showed — a more complicated picture emerges. One that is less about protecting patients and more about protecting markets.

To understand the restriction, you have to understand the legal architecture. Under the FDA Drug Quality and Security Act, compounding pharmacies are permitted to prepare customized drug products for individual patients under two frameworks: Section 503A (state-licensed pharmacies serving individual patient prescriptions) and Section 503B (larger outsourcing facilities). Both are only permitted to compound using substances that appear on an approved bulks list — or that meet specific legal criteria.

On September 29, 2023, the FDA updated its interim policy and placed 19 peptides into Category 2 — a designation that effectively prohibited any 503A or 503B entity from compounding them. No pharmacy in the United States could legally produce these substances. The peptides banned included BPC-157, TB-500 (Thymosin Beta-4), Ipamorelin, CJC-1295, Selank, Epithalon, and more — compounds that physicians across the country had been prescribing for years for wound healing, recovery, inflammation, and hormonal support.

The GLP-1 story is the clearest lens through which to understand the broader peptide suppression dynamic. When semaglutide (Ozempic, Wegovy) shortages emerged in 2022, the FDA permitted compounding pharmacies to fill the gap under a shortage exception. Millions of Americans accessed the medication at a fraction of the branded cost. Then, as Novo Nordisk ramped production and resolved the shortage, the FDA moved quickly to close that door permanently.

By early 2025, 503A compounders were legally prohibited from producing semaglutide. By mid-2025, 503B outsourcing facilities followed. The FDA's justification: the shortage was resolved, so the exception no longer applied. But what this framing obscures is the effect — not the cause. The effect was that a billion-dollar drug suddenly had its cheaper competition legally eliminated. Whether that was intent or consequence is a question worth sitting with.

The FDA's stated rationale for the 2023 peptide restrictions — immunogenicity risk, manufacturing impurities, and lack of large-scale human trials — deserves genuine scrutiny, not dismissal. These are real considerations in pharmaceutical safety. But they must be evaluated in context. The very substances deemed too unsafe for regulated compounding pharmacies (with licensed pharmacists, USP standards, and state oversight) were simultaneously available from completely unregulated research vendors with zero accountability. If the concern was truly patient safety, the ban accomplished the opposite.

There's also the question of process. The FDA bypassed its own Pharmacy Compounding Advisory Committee — the public review body specifically designed to evaluate substances for safety and appropriateness in compounding. The September 2024 settlement, in which the FDA agreed to halt its unilateral ban and submit peptides to that review process, was essentially an acknowledgment that the proper process had been circumvented. Legal pressure forced the FDA back to doing what it should have done first.

“Critics — including clinicians, compounding pharmacists, and members of Congress — argued the ban was regulatory overreach that pushed patients toward unregulated grey-market sources.”

On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of the 19 banned peptides would be restored to legal compounding access. It was framed as a win for patient freedom and alternative medicine. And in many ways, it was. But the reversal itself is telling: if the original ban was scientifically justified on safety grounds, what changed in the data between 2023 and 2026? The peptides didn't become safer. New clinical trials weren't completed. What changed was political will and, arguably, public pressure.

The fact that a regulatory designation made on ostensibly scientific grounds can be reversed by a political appointee's announcement — without any new safety data — suggests the original restriction was never purely about science. It was a policy choice dressed in scientific language. That distinction is important, because it means the next administration could reverse the reversal just as easily. Access to peptides, it turns out, is not determined by the weight of evidence. It's determined by who's in power.

None of this means the FDA is uniformly corrupt, that all pharmaceutical companies act in bad faith, or that every peptide is proven safe for all uses. The world is more nuanced than that, and good-faith safety concerns exist alongside institutional conflicts of interest. What it does mean is that you cannot take regulatory status as a neutral, purely scientific signal. The absence of FDA approval does not mean a substance is dangerous. The presence of a ban does not mean the primary concern was your safety.

The story of peptide suppression in America is still being written. Fourteen compounds have been partially restored. Five remain restricted. GLP-1 compounding access is being closed even as you read this. The forces that shaped the 2023 ban haven't gone anywhere — they've simply shifted their focus. Staying informed isn't just useful. In this landscape, it's necessary.